Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
immunotherapy
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April...
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and...
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...
Immuron Q3 Sales reach 150% of 1H Sales
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
ILAP Designation accelerates patient access and commercializationMIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”),...
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated...
Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France...
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
SIOUX FALLS, S.D., April 04, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a...
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming...
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France...
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
Enochian BioSciences’ CEO Letter to Shareholders
Turning the Page; A Promising FutureLOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug...
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or...
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company,...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic...
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...